NCT01627041View on ClinicalTrials.gov

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

September 16, 2011

Primary Completion Date

February 11, 2016

Study Completion Date

February 1, 2026

Conditions
Acute Myeloid LeukemiaAdult Acute Basophilic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2AAdult Acute Myeloid Leukemia Without MaturationAdult Acute Myelomonocytic LeukemiaAlkylating Agent-Related Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia
Interventions
DRUG

Cytarabine

Given IV

DRUG

Daunorubicin Hydrochloride

Given IV

DRUG

Decitabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (9)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

NYP/Weill Cornell Medical Center, New York

10461

Montefiore Medical Center-Weiler Hospital, The Bronx

10467

Montefiore Medical Center - Moses Campus, The Bronx

14263

Roswell Park Cancer Institute, Buffalo

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western Reserve University, Cleveland

04412

Lafayette Family Cancer Center-EMMC, Brewer

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH